



Supplementary Figure 2. CfDNA concentration in patients with HER2-negative breast cancers. CfDNA concentration was measured in the plasma of patients with hormone receptor-positive HER2-negative (HR+HER2-) and triple-negative breast cancer (TNBC). P values were calculated using the Wilcoxon rank sum test. Blood was collected at pretreatment (T0), 3 weeks after treatment initiation (T1), 12 weeks after treatment initiation between paclitaxel-based treatment and anthracycline regimens (T2), and after neoadjuvant chemotherapy before surgery (T3).